The following is a summary of “Plasma Serotonin and Cardiovascular Outcomes in Chronic Kidney Disease,” published in the August 2023 issue of Cardiology by Edmonston et al.
Researchers performed a prospective study to determine the relationship between platelet-poor plasma serotonin levels and cardiovascular outcomes in patients with chronic kidney disease.
They assessed the association between plasma serotonin levels (categorized as undetectable, intermediate, and high ≥20 ng/mL) and echocardiographic findings, cardiovascular outcomes including heart failure hospitalization, atherosclerotic cardiovascular disease events (ASCVD), and mortality in 1,114 participants from the prospective CRIC (Chronic Renal Insufficiency Cohort) Study. The impact of selective serotonin reuptake inhibitors on the serotonin-outcome relationship was also assessed.
The results showed plasma serotonin levels exhibited an inverse relationship with estimated glomerular filtration rate while directly correlating with blood pressure. Elevated plasma serotonin levels corresponded with left ventricular hypertrophy (adjusted odds ratio: 2.74 [95% CI: 1.11–7.41]). Conversely, having undetectable plasma serotonin levels correlated with the highest risk of heart failure (adjusted hazard ratio [HR]: 2.26 [95% CI: 1.40–3.66]) and ASCVD events (adjusted HR: 1.96 [95% CI: 1.15–3.32]).
Investigators concluded low and high plasma serotonin levels were associated with ASCVD risk in people with chronic kidney disease.